Streetbeat News

Revenues

MFIC

Analysts have recently updated their ratings and price targets for MidCap Financial (NASDAQ:MFIC), showing a mix of bullish and indifferent stances. Over the past three months, four analysts have provided insights, with the latest updates indicating an average 12-month price target of $15.00, up from the previous $14.00. This reflects a positive sentiment shift, with upgrades from analysts at RBC Capital, Truist Securities, JP Morgan, and Wells Fargo. MidCap Financial, a Business Development Company focusing on senior debt solutions for middle market companies, has shown significant revenue growth and profitability, despite some challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 4:00 pm

JNJ

13 analysts have provided diverse opinions on Johnson & Johnson (JNJ) over the past quarter, with sentiments ranging from bullish to bearish. The average 12-month price target for JNJ has been raised to $191.0, indicating a 10.72% increase from the previous target of $172.50. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to JNJ's market performance. JNJ's financial performance shows solid revenue growth, exceptional net margin, and strong ROE and ROA, with a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 4:00 pm

NVAX

Novavax Inc (NASDAQ:NVAX) reported a Q4 2023 revenue of $291 million, missing the consensus of $321.97 million, and a net loss of $178 million. The company's full-year 2023 revenue was $984 million, down from $2 billion in 2022. EPS loss for Q4 was $(1.44), worse than the consensus of $(0.45). Novavax announced workforce reductions and a settlement with Gavi over a 2021 advance purchase agreement. The company forecasts 2024 revenue of $800 million-$1 billion, below the consensus of $969.56 million. NVAX shares dropped 29.30% to $4.25.

Portfolio Pulse from Vandana Singh

February 28, 2024 | 3:52 pm

BMY

LLY

NVO

Eli Lilly (LLY) plans to introduce its obesity drug, tirzepatide, in India next year, competing with Novo Nordisk's (NVO) Wegovy. Bristol Myers Squibb (BMY) is expanding its R&D in India, with a $100-million facility in Hyderabad to become its largest unit outside the U.S. by 2025. The companies aim to tap into the Indian market, emphasizing the need for better patent protection and policy reforms in India.

Portfolio Pulse from Vandana Singh

February 28, 2024 | 3:46 pm

ACB

CURLF

TLRY

Pablo Zuanic forecasts Germany's medical cannabis market to grow to €1.7 billion by 2025, driven by legislative changes and increased accessibility. Canadian companies Aurora (ACB) and Tilray (TLRY), along with Curaleaf (CURLF) through its German subsidiary Four20 Pharma, are well-positioned to benefit from this growth. The introduction of cannabis social clubs and easier prescription processes are key growth drivers.

Portfolio Pulse from Nicolás Jose Rodriguez

February 28, 2024 | 3:45 pm

UGA

USO

XOM

Gasoline pump prices have surged to near a 1-year high, with the national average reaching $3.30 a gallon, driven by rising crude oil prices amid Middle East tensions and attacks on oil shipments. The United States Oil Fund (USO) and the United States Gasoline Fund ETF (UGA) have seen significant movements, with USO near a three-month high. The situation is exacerbated by falling gasoline stockpiles and potential refinery disruptions due to severe weather in the Midwest, affecting facilities like Exxon Mobil Corp's (XOM), Citgo's, and BP Plc's (BP). This rise in fuel prices could influence inflation expectations and the Federal Reserve's rate cut decisions.

Portfolio Pulse from Neil Dennis

February 28, 2024 | 3:39 pm

NIO

TSLA

XPEV

Li Auto Inc. (NASDAQ:LI) reported strong fourth-quarter results with triple-digit revenue growth and improved margins, but forecasted a significant slowdown in growth for the current quarter. The Chinese NEV sector is facing a slowdown, exacerbated by negative media reports and consumer concerns. Li Auto's shares surged nearly 20% following the announcement. The company outperformed rivals like Xpeng, Nio, and Tesla in terms of price-to-sales ratio, reflecting investor confidence in its long-term viability. However, the overall NEV sector in China is expected to face challenges in 2024, including a slowdown in sales growth and negative publicity surrounding NEV safety.

Portfolio Pulse from The Bamboo Works

February 28, 2024 | 3:16 pm

SEE

Analysts have mixed views on Sealed Air (NYSE:SEE), with recent evaluations showing a shift towards a more positive outlook. The average 12-month price target has increased to $40.5, up 6.58% from $38.00. Analyst actions include adjustments to ratings and price targets, reflecting responses to market dynamics and company performance. Sealed Air's financial indicators reveal challenges in revenue growth but strong profitability and financial management, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 3:01 pm

AMT

Analysts have provided diverse opinions on American Tower (AMT) with a mix of bullish and somewhat bullish ratings over the past quarter. The average 12-month price target is $231.75, slightly down from the previous $233.33. Analysts from JP Morgan, BMO Capital, Barclays, and HSBC have adjusted their price targets, reflecting changes in market conditions and company performance. American Tower, operating as an REIT, owns over 220,000 cell towers globally and has shown a revenue growth of 5.51% over the past 3 months, though its net margin and ROA are below industry averages.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 3:00 pm

GSAT

Globalstar, Inc (NYSE: GSAT) reported a 27% year-on-year increase in Q4 fiscal 2023 sales to $52.4 million, slightly below the consensus of $52.9 million. The company's EPS was $0.01, beating the consensus of $0.00, but its stock price declined post-results. Adjusted EBITDA rose 37% Y/Y to $25.1 million, while the loss from operations and net loss increased. GSAT expects FY24 revenue of $225 million to $250 million, below the consensus of $251.5 million, and an adjusted EBITDA margin of about 50%. GSAT shares dropped 3.45% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 28, 2024 | 2:27 pm